NCT03625401 - Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Alzheimer Disease, Early Onset

Interventions

DRUG

AD-35 60mg group

AD-35 60mg QD

DRUG

Placebo group

Placebo: 3 placebo of AD-35 30mg tablets

Trial Locations (10)

Clinilabs, Inc., New York

NeuroStudies, Decatur

Meridien Research, Maitland

Brain Matters Research, Delray Beach

Neuropsychiatric Research Center of Southwest Florida, Fort Myers

Meridien Research, Spring Hill

Alexian Brothers Neurosciences Institute, Elk Grove Village

Pacific Research Network, Inc., San Diego

Northern California Research, Sacramento

Advanced Memory Research Institute of NJ, Toms River